enzastaurin has been researched along with Lymphoma, Mantle-Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
| Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y | 1 |
| Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
| Cartron, G; Dreyling, M; Grigg, A; Kluin-Nelemans, HC; Milpied, N; Morschhauser, F; Pezzutto, A; Pfreundschuh, M; Raemaekers, J; Reyes, F; Seymour, JF; Spencer, A; Tilly, H; van 't Veer, MB; Wolf, M | 1 |
1 trial(s) available for enzastaurin and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Recurrence; Survival Analysis; Treatment Outcome | 2008 |
3 other study(ies) available for enzastaurin and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide | 2015 |
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2010 |
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Everolimus; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Indoles; Lymphoma, Mantle-Cell; Phosphorylation; Phosphorylcholine; Protein Kinases; Quinolines; Sirolimus | 2012 |